China Pediatric Devices and Diagnostics Expected To More Funding and Growth

Reimbursement Change Calls for Quality IVD
February 16, 2018
Trump Tariffs Will Hurt U.S. Medtech Companies More
April 5, 2018

China Pediatric Devices and Diagnostics Expected To More Funding and Growth

In the National People’s Congress (NPC) and the Chinese People’s Political Consultative Conference (CPPCC) that are being held, representatives and committee members have all suggested that R & D for pediatric drugs and medical devices should be vigorously supported.

Due to second-child policy adopted in late 2016, the number of children in China will reach 260 million by 2020, providing greater opportunities for the market for children’s medical devices.

For the research and development of pediatric drugs, medical equipment and diagnostics, NPC deputies and CPPCC members proposed the inclusion of children’s medical services in major national science and technology projects. Accelerating children’s innovative research and development of medical devices, standardizing the management of children’s medical services, and simultaneously enabling children to benefit from the latest research results, is also a hot topic of current healthcare reform in China.

 

About China Med Device, LLC

China Med Device, LLC provides turn-key solutions for western medical device/IVD companies to enter China with regulation and commercialization services. Our CFDA regulatory services cover strategy, premarket submission, clinical evaluation, CRO, post market compliance as well as legal agent representation. Our commercial services cover market assessment research, reimbursement, partnership, distribution qualification and management. We have an office in Beijing, Suzhou and Boston. Our management team have 100+ years of combined experience in medical device and IVD and had been involved with 1,000+ CFDA certificates, 200+ western companies’ entry.